Oxcarbazepine experienced with carbamazepine, toxic epidermal necrolysis, Stevens–Johnson syndrome, and thoughts of suicide. Measurement of serum sodium levels should be considered in maintenance treatment or if symptoms of hyponatremia develop. Low blood sodium is seen in 20-30% of people taking oxcarbazepine and 8-12% of those who have oxcarbazpine-induced hyponatremia experience severe hyponatremia. Some side effects (such as headache) are more pronounced shortly after a dose is taken and tend to fade with the passage of time (60 to 90 minutes). Other side effects include stomach pain, tremor, rash, diarrhea, constipation, decreased appetite and dry mouth. Photosensitivity is a potential side-effect and
Serum sickness an alternate antitoxin if it's appropriate or continue with prophylactic measures. Serum sickness Serum sickness in humans is a reaction to proteins in antiserum derived from a non-human animal source, occurring 5–10 days after exposure. It is a type of hypersensitivity, specifically immune complex hypersensitivity (type III). The term serum sickness–like reaction (SSLR) is occasionally used to refer to similar illnesses that arise from the introduction of certain non-protein substances, such as penicillin. It was first characterized by Clemens von Pirquet and Béla Schick in 1906. When an antiserum is given, the human immune system can mistake the proteins present